Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | YTHDF3 | Q7Z739 | 1/20 | 0.33 |
| ▸ | YTHDF1 | Q9BYJ9 | 1/20 | 0.33 |
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | PDE1A | P54750 | 1/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5763194 | 0.75 | PDE5A (0.39) | LMNAPDE5APDE1APDE1BPDE3B | |
| SCHEMBL13455320 | 0.74 | PDE5A (0.41) | LMNAPDE5APDE1APDE1BPDE3B | |
| SCHEMBL16060013 | 0.71 | — | — | |
| SCHEMBL1789261 | 0.66 | ATM (0.50) | LMNAALDH1A1 | |
| SCHEMBL16082062 | 0.64 | ADORA2A (0.38) | LMNADAONOTUMALDH1A1 | |
| SCHEMBL21405574 | 0.62 | JAK2 (0.33) | — | |
| SCHEMBL4621674 | 0.60 | — | — | |
| SCHEMBL5254237 | 0.60 | — | — | |
| SCHEMBL15564067 | 0.60 | — | — | |
| SCHEMBL1617042 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4574821-B1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-3893889-B1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260001867-A1 | THR BETA RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS PHARMACEUTICALS, INC. | 2026-01-01 | — | — | US | disclosed |
| US-12459926-B2 | THRβ receptor agonist compound and preparation method and use thereof | Terns, Inc. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12365669-B2 | THRβ receptor agonist compound and preparation method and use thereof | Terns, Inc. (US) | 2025-07-22 | — | — | US | disclosed |
| EP-4574821-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | Terns, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12338232-B2 | THRβ receptor agonist compound and preparation method and use thereof | Terns, Inc. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250179054-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS PHARMACEUTICALS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250179053-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS PHARMACEUTICALS, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4529954-A2 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | Terns, Inc. (US) | 2025-04-02 | — | — | EP | disclosed |
| CN-116444498-A | THR beta receptor agonist compound, preparation method and application thereof | 拓臻股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-113194958-B | THR beta receptor agonist compound, preparation method and application thereof | 拓臻股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-3893889-A1 | THR? RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | Terns, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-11084802-B2 | THRβ receptor agonist compound and preparation method and use thereof | Terns, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| CN-113194958-A | THR beta receptor agonist compound and preparation method and application thereof | 拓臻股份有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-11034676-B2 | THRB receptor agonist compound and preparation method and use thereof | Terns, Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200399249-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
| CN-111320609-A | THR β receptor agonist compound and preparation method and application thereof | 拓臻股份有限公司 | 2020-06-23 | — | — | CN | disclosed |
| WO-2020123827-A1 | THRΒ RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | Terns, Inc. (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20200190064-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS PHARMACEUTICALS, INC. | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179054-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | THRB, THRA, TRHR | LMNA 3560/4885RECQL 4861/4885YTHDF3 3559/4885 |
| US-20260001867-A1 | THR BETA RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | THRB, THRA, ADRB1 | LMNA 1756/4885RECQL 4871/4885YTHDF3 3358/4885 |
| US-20250179053-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | THRB, THRA, TRHR | LMNA 3560/4885RECQL 4861/4885YTHDF3 3559/4885 |
| US-20200190064-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | THRB, THRA, TRHR | LMNA 3560/4885RECQL 4861/4885YTHDF3 3559/4885 |
| US-12459926-B2 | THRβ receptor agonist compound and preparation method and use thereof | THRB, THRA, TRHR | LMNA 3444/4885RECQL 4860/4885YTHDF3 3412/4885 |
| US-12365669-B2 | THRβ receptor agonist compound and preparation method and use thereof | THRB, THRA, TRHR | LMNA 3444/4885RECQL 4860/4885YTHDF3 3412/4885 |
| US-11034676-B2 | THRB receptor agonist compound and preparation method and use thereof | THRB, THRA, TRHR | LMNA 3560/4885RECQL 4861/4885YTHDF3 3559/4885 |
| US-11084802-B2 | THRβ receptor agonist compound and preparation method and use thereof | THRB, THRA, TRHR | LMNA 3444/4885RECQL 4860/4885YTHDF3 3412/4885 |
| US-12338232-B2 | THRβ receptor agonist compound and preparation method and use thereof | THRB, THRA, TRHR | LMNA 3444/4885RECQL 4860/4885YTHDF3 3412/4885 |
| US-20200399249-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | THRB, THRA, TRHR | LMNA 3560/4885RECQL 4861/4885YTHDF3 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.